Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) EBT (2021 - 2025)

Prime Medicine filings provide 5 years of EBT readings, the most recent being -$47.5 million for Q4 2025.

  • On a quarterly basis, EBT fell 12.42% to -$47.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$204.8 million, a 4.57% decrease, with the full-year FY2025 number at -$204.2 million, down 4.25% from a year prior.
  • EBT hit -$47.5 million in Q4 2025 for Prime Medicine, up from -$52.8 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$18.8 million in Q3 2021 to a low of -$65.6 million in Q4 2023.
  • Median EBT over the past 5 years was -$46.6 million (2024), compared with a mean of -$44.6 million.
  • Biggest five-year swings in EBT: surged 35.85% in 2022 and later plummeted 74.4% in 2023.
  • Prime Medicine's EBT stood at -$61.5 million in 2021, then surged by 35.85% to -$39.5 million in 2022, then crashed by 66.32% to -$65.6 million in 2023, then surged by 35.6% to -$42.3 million in 2024, then decreased by 12.42% to -$47.5 million in 2025.
  • The last three reported values for EBT were -$47.5 million (Q4 2025), -$52.8 million (Q3 2025), and -$52.6 million (Q2 2025) per Business Quant data.